Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany
Business Of Biotech
00:00
How BI Discovered the Interleukin 36 Antibody
Spasolomab is a selective antibody that blocks the activation of the interleukin 36 receptor, which is a key part of a signaling pathway within the immune system. This antibody by blocking the receptors blocks the binding of ligand that would typically activate the pathway downstream of it. And because of that, the this over activation of the innate immune system is sort of stabilized and the system goes back to normalcy.
Transcript
Play full episode
